EP3720470A4 - IL-2 MUTEINS AND THEIR USES - Google Patents

IL-2 MUTEINS AND THEIR USES Download PDF

Info

Publication number
EP3720470A4
EP3720470A4 EP18887098.4A EP18887098A EP3720470A4 EP 3720470 A4 EP3720470 A4 EP 3720470A4 EP 18887098 A EP18887098 A EP 18887098A EP 3720470 A4 EP3720470 A4 EP 3720470A4
Authority
EP
European Patent Office
Prior art keywords
muteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18887098.4A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3720470A1 (en
Inventor
Nathan HIGGINSON-SCOTT
Joanne L. Viney
Jyothsna Visweswaraiah
Erik Robert Sampson
Kevin Lewis Otipoby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pandion Operations Inc
Original Assignee
Pandion Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/109,875 external-priority patent/US10174091B1/en
Application filed by Pandion Operations Inc filed Critical Pandion Operations Inc
Publication of EP3720470A1 publication Critical patent/EP3720470A1/en
Publication of EP3720470A4 publication Critical patent/EP3720470A4/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
EP18887098.4A 2017-12-06 2018-11-28 IL-2 MUTEINS AND THEIR USES Pending EP3720470A4 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762595357P 2017-12-06 2017-12-06
US201862675972P 2018-05-24 2018-05-24
US201862721644P 2018-08-23 2018-08-23
US16/109,875 US10174091B1 (en) 2017-12-06 2018-08-23 IL-2 muteins
US16/109,897 US10174092B1 (en) 2017-12-06 2018-08-23 IL-2 muteins
PCT/US2018/062808 WO2019112854A1 (en) 2017-12-06 2018-11-28 Il-2 muteins and uses thereof

Publications (2)

Publication Number Publication Date
EP3720470A1 EP3720470A1 (en) 2020-10-14
EP3720470A4 true EP3720470A4 (en) 2021-09-15

Family

ID=66751187

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18887098.4A Pending EP3720470A4 (en) 2017-12-06 2018-11-28 IL-2 MUTEINS AND THEIR USES

Country Status (11)

Country Link
EP (1) EP3720470A4 (zh)
JP (1) JP7250790B2 (zh)
KR (2) KR20240039201A (zh)
CN (1) CN111432831A (zh)
AU (1) AU2018378078A1 (zh)
BR (1) BR112020011343A2 (zh)
CA (1) CA3083941A1 (zh)
IL (1) IL274844A (zh)
MX (1) MX2020005208A (zh)
SG (1) SG11202003965VA (zh)
WO (1) WO2019112854A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190129077A (ko) 2017-03-15 2019-11-19 팬디온 테라퓨틱스, 인코포레이티드 표적화된 면역관용
MX2019013517A (es) 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
JP2022533702A (ja) 2019-05-20 2022-07-25 パンディオン・オペレーションズ・インコーポレイテッド MAdCAM標的化免疫寛容
CN114728179A (zh) * 2019-08-19 2022-07-08 潘迪恩运营公司 利用pd-1激动剂的靶向免疫耐受
CN110642934B (zh) * 2019-09-10 2022-08-23 中国医学科学院北京协和医院 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
WO2021076805A1 (en) 2019-10-15 2021-04-22 Moderna TX, Inc. Mrnas encoding immune modulating polypeptides and uses thereof
CN112358540A (zh) * 2020-11-03 2021-02-12 安徽环球基因科技有限公司 一种重组il2在毕赤酵母中的生产方法
TW202345889A (zh) * 2022-03-03 2023-12-01 大陸商海南先聲藥業有限公司 IL2突變體-抗體Fc嵌段融合蛋白的藥物組合物及其應用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1007907B (zh) * 1985-04-30 1990-05-09 弗·哈夫曼-拉罗彻有限公司 重组人类白细胞介素-2的提纯
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
US9428567B2 (en) * 2010-12-22 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of interleukin-2 receptor
WO2012164021A1 (en) * 2011-05-31 2012-12-06 Novo Nordisk A/S Il-21 epitope and il-21 ligands
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
DK3172227T3 (da) * 2014-07-21 2019-12-02 Delinia Inc Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme
CN115073581A (zh) * 2016-05-04 2022-09-20 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
WO2018184965A1 (en) * 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
MX2019013517A (es) 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
EP3720871A4 (en) 2017-12-06 2021-09-15 Pandion Operations, Inc. TARGETED IMMUNTOLERANCE

Also Published As

Publication number Publication date
AU2018378078A1 (en) 2020-06-18
WO2019112854A1 (en) 2019-06-13
KR20240039201A (ko) 2024-03-26
CN111432831A (zh) 2020-07-17
JP7250790B2 (ja) 2023-04-03
JP2021507690A (ja) 2021-02-25
BR112020011343A2 (pt) 2020-11-17
CA3083941A1 (en) 2019-06-13
SG11202003965VA (en) 2020-06-29
KR20200097275A (ko) 2020-08-18
EP3720470A1 (en) 2020-10-14
MX2020005208A (es) 2020-08-20
IL274844A (en) 2020-07-30

Similar Documents

Publication Publication Date Title
EP3720470A4 (en) IL-2 MUTEINS AND THEIR USES
EP3681888A4 (en) PYRAZOLOPYRIMIDINONE COMPOUNDS AND THEIR USES
EP3720502A4 (en) CYTOBIOLOGICAL PRODUCTS AND THEIR THERAPEUTIC USES
EP3733693A4 (en) IL-2 VARIANT
EP3453401A4 (en) INTERLEUKIN COMBINATION AND THEIR USE
EP3841096A4 (en) PYRIDINYLMETHYLENEPIPERIDEINDIVATES AND THEIR USES
EP3758778A4 (en) MEDICAL DEVICES AND THEIR USES
EP3511407A4 (en) CHRISTENSENELLA INTESTINIHOMINIS AND ITS APPLICATION
EP3902530A4 (en) POLYMER NANOVACCINE AND USES THEREOF
EP3638251A4 (en) BISPHOSPHOCIN GEL FORMULATIONS AND THEIR USES
EP3700934A4 (en) COMPOUNDS AND USES OF THESE COMPOUNDS
EP3687501A4 (en) INIPARIB FORMS AND USES THEREOF
EP3808357A4 (en) COMPOSITION AND USES THEREOF
EP3762364A4 (en) PYRROLIDINEAMIDE DERIVATIVES AND THEIR USES
EP3691629A4 (en) NUTRIENT SPORE FORMULATIONS AND THEIR USES
EP3730565A4 (en) MULTI-LAYER STRUCTURE AND ITS USES
EP3683303A4 (en) MEGAMONAS FUNIFORMIS AND USE OF IT
EP3856755A4 (en) TERPINOID DERIVATIVES AND THEIR USES
EP3746077A4 (en) PARENTERAL FORMULATIONS AND USES THEREOF
EP3665191A4 (en) SPECIFIC BRAF TCRs AND RELATED USES
EP3689887A4 (en) COMPOSITION AND ELECTROLUMINESCENT DEVICE USING THE SAME
EP3729351A4 (en) FAST AND SHEET RESILIENT BLOCK STRINGS
EP3684796A4 (en) SUCCINATE REGULATORY POLYPEPTIDES AND USES
EP3635324A4 (en) REVERSE FREEZING COMPOSITIONS AND USE OF THEM
EP3611181A4 (en) ATP1A1T TARGETING POLYPEPTIDE AND USES

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200605

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: VISWESWARAIAH, JYOTHSNA

Inventor name: SAMPSON, ERIK ROBERT

Inventor name: OTIPOBY, KEVIN LEWIS

Inventor name: VINEY, JOANNE L.

Inventor name: HIGGINSON-SCOTT, NATHAN

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PANDION OPERATIONS, INC.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40039617

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20210813

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/06 20060101ALI20210809BHEP

Ipc: A61P 37/04 20060101ALI20210809BHEP

Ipc: A61P 37/02 20060101ALI20210809BHEP

Ipc: A61P 29/00 20060101ALI20210809BHEP

Ipc: A61K 47/68 20170101ALI20210809BHEP

Ipc: A61K 38/20 20060101AFI20210809BHEP